Cipla CEO Sees 5-10% Monthly Sales Growth for Yurpeak
Cipla’s global CEO sees monthly sales of its obesity drug Yurpeak growing 5-10%.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.